The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

After paying almost $200 to get a shingles vaccine they later learned is publicly funded, a Tillsonburg, Ont., couple says ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Dynavax Technologies Corp. (DVAX) on Thursday said that its experimental Shingles vaccine yielded positive results in an ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

The recombinant herpes zoster vaccine (Shingrix) was not only associated with a reduced risk of herpes zoster ophthalmicus ...

Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from ...

L-lysine is an essential amino acid. Another amino acid, arginine, counteracts the antiviral action of lysine. As a result, L ...

Whether you’re a teenager, planning a pregnancy, or in your golden years, the right immunizations can prevent life-altering ...